Core Viewpoint - *ST Suwu has been found guilty of serious financial fraud over multiple years, leading to potential delisting due to major violations of stock listing rules [1][3]. Group 1: Financial Misconduct - From 2020 to 2023, *ST Suwu inflated its operating income by approximately 4.95 billion, 4.69 billion, 4.31 billion, and 3.77 billion respectively, accounting for 26.46%, 26.39%, 21.26%, and 16.82% of the reported operating income for those years [2]. - The company also inflated its total profit by 14.58 million, 20.27 million, 19.92 million, and 21.22 million, representing 2.89%, 51.65%, 26.42%, and 29.81% of the total profit for the respective years [2]. - Non-operational fund occupation by related parties was not disclosed in annual reports from 2020 to 2023, with balances of 127 million, 1.39 billion, 1.54 billion, and 1.69 billion at year-end, constituting 6.88%, 74.20%, 84.60%, and 96.09% of the net assets [2]. Group 2: Regulatory Actions - Starting July 14, *ST Suwu's stock will be subject to delisting risk warnings due to the serious violations identified [3]. - The company is required to disclose progress on related matters every five trading days during the delisting risk warning period and must provide special risk warnings regarding potential mandatory delisting [3]. - The company has issued over 20 risk warning announcements since being investigated, indicating the ongoing nature of the delisting risk [4]. Group 3: Investor Protection and Accountability - The regulatory authorities have adopted a "zero tolerance" approach towards financial fraud, emphasizing that companies facing delisting will still be held accountable for their fraudulent actions [5]. - Even after delisting, *ST Suwu will remain liable for civil compensation related to its fraudulent activities, ensuring that investors can seek redress for damages incurred [5]. - The Supreme People's Court and the China Securities Regulatory Commission have issued guidelines to strengthen legal protections for investors against fraudulent activities [6].

江苏吴中医药发展股份有限公司(以下简称"公司") 因涉嫌信息披露违 法违规，被中国证券监督管理委员会（以下简称"中国证监会"）立案 调查。2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先 告知书》（处罚字〔2025〕58 号）。认定公司虚增营业收入、营业成本 和利润，2020 年至 2023 年年度报告存在虚假记载。 如根据正式的处罚决定书结论，公司触及重大违法强制退市情形，公司 股票将被终止上市。根据《上海证券交易所股票上市规则》第 9.5.7 条、 第 9.5.8 条，如公司后续收到行政处罚决定书，显示公司触及重大违法 类强制退市情形，公司将申请停牌，并及时披露有关内容。上海证券交 易所将在停牌之日起的 5 个交易日内，向公司发出拟终止股票上市的事 先告知书，后续将根据《上海证券交易所股票上市规则》的相关规定， 作出是否终止公司股票上市的决定。 公司将全力配合中国证监会的相关工作，并积极行使听证或进行陈述、 申辩等合法权利，维护公司和广大投资者权益，最终结果以中国证监会 出具的正式处罚决定为准。敬请广大投资者关注后续公告并注意投资风 险。 法》《中华人民共和国行政处罚法》等法律法规， ...

公司 2024 年度财务报告内部控制被年审机构出具无法表示意见；浙江复基 控股集团有限公司的其他关联方企业存在非经营性占用公司资金的情形。上述事 项触及《上海证券交易所股票上市规则》第 9.8.1 条第（一）（三）项的规定， 公司被叠加实施其他风险警示。具体内容详见公司于 2025 年 5 月 6 日披露的《关 于控股股东关联方资金占用暨叠加其他风险警示的公告》（公告编号：临 2025-034）。 证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-066 江苏吴中医药发展股份有限公司 关于叠加实施退市风险警示的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 一、公司已被实施的退市风险警示和其他风险警示 江苏吴中医药发展股份有限公司（以下简称"公司"）因公司 2024 年度财 务报告被年审机构出具无法表示意见，触及《上海证券交易所股票上市规则》第 9.3.2 条第（三）项规定财务类退市的情形，公司股票已被上海证券交易所实施 退市风险警示。具体内容详见公司于 2025 年 4 月 30 日披露的《关于实施退市 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-064 江苏吴中医药发展股份有限公司关于收到 中国证券监督管理委员会《行政处罚事先告知书》的公告 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司（以下简称"公司"）于 2025 年 2 月 26 日收到中国证券监督管理委员会（以下简称"中国证监会"）《立案告知书》（证 监立案字 0392025006 号），因公司涉嫌信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公 司立案。具体内容详见公司于 2025 年 2 月 27 日披露的《关于收到中国证券监督 管理委员会立案告知书暨风险提示公告》（公告编号：临 2025-007）。 2025 年 5 月 15 日，公司披露《关于公司董事长收到立案告知书的公告》（公 告编号：临 2025-038），公司董事长因涉嫌信息披露违法违规，中国证监会决 定对其立案。 2025 年 7 月 13 日，公司收到中国证监会下发的《行政处罚事先告知书》 ...

Core Viewpoint - *ST Suwu (600200) is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws, which may lead to significant penalties and potential delisting of its shares [1] Summary by Relevant Sections - **Investigation Details** - The company received a notice of administrative penalty on July 13, 2025, indicating that its annual reports from 2020 to 2023 contained false records, including inflated revenue, costs, and profits [1] - **Potential Consequences** - If the formal penalty decision confirms the findings, the company may face mandatory delisting due to serious violations of laws [1] - **Company's Response** - The company has stated it will fully cooperate with the investigation and actively exercise its legal rights [1]

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-063 江苏吴中医药发展股份有限公司 关于立案调查进展暨风险提示公告 截至本公告披露日，中国证监会的调查尚在进行中，公司尚未收到就上述立 案调查事项的结论性意见或决定。在立案调查期间，公司积极配合中国证监会的 相关调查工作。 若后续经中国证监会行政处罚认定的事实，触及《上海证券交易所股票上市 规则》规定的重大违法强制退市情形，公司股票将被实施重大违法强制退市。请 投资者理性投资，注意投资风险。 公司目前日常生产经营正常，市场环境或行业政策未发生其他重大变化。公 司郑重提醒广大投资者，公司指定信息披露媒体为《中国证券报》《上海证券报》 及上海证券交易所网站（www.sse.com.cn），公司所有信息均以上述指定媒体刊 登的正式公告为准,敬请广大投资者理性投资,注意投资风险。 特此公告。 江苏吴中医药发展股份有限公司 董事会 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 重要风险提示： 江苏吴中医药发展股份有限公司(以下简称"公司")目前存在多重退市 风险，敬请 ...

证券代码：600200 证券简称：*ST 苏吴 公告编号：临 2025-062 江苏吴中医药发展股份有限公司 关于 2024 年年度股东大会决议的更正公告 6.03 议案名称：江苏吴中医药集团有限公司苏州制药厂，最高担保额 4,000 万元 更正后： 二、议案审议情况 (一)非累积投票议案 6.03 议案名称：江苏吴中医药销售有限公司，最高担保额 40,000 万元 除上述更正内容外，公司 2024 年年度股东大会决议公告中其他内容均未发 生变化。公司对上述更正给投资者带来的不便深表歉意，敬请广大投资者谅解。 今后公司将进一步强化信息披露审核工作，提高信息披露质量。 本公司董事会及董事会全体成员保证公告内容不存在虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实、准确和完整承担法律责任。 江苏吴中医药发展股份有限公司(以下简称"公司")于 2025 年 5 月 22 日披 露了《江苏吴中医药发展股份有限公司 2024 年年度股东大会决议公告》（公告 编号：2025-042）。经事后核查，发现议案名称有误，现就原公告的部分内容予 以更正，具体更正内容如下： 更正前： 二、议案审议情况 (一)非累积投票议案 特 ...

Group 1 - The stock price of *ST Suwu (600200) closed at 2.44 yuan on July 4, 2025, down 3.17% with a turnover rate of 4.71% and a trading volume of 334,700 hands, amounting to 82.78 million yuan [1] - The latest financial report for *ST Suwu shows total operating revenue of 317 million yuan for Q1 2025, a year-on-year decrease of 25.44%, and a net profit attributable to shareholders of 70.32 million yuan, down 1489.93% year-on-year [1] - The company has a current ratio of 1.477, a quick ratio of 1.426, and a debt-to-asset ratio of 54.16% [1] Group 2 - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. was established in 1994 and is primarily engaged in the pharmaceutical manufacturing industry, located in Suzhou [2] - The company has made investments in 12 enterprises and participated in 5 bidding projects, holding 47 trademark registrations and 2 patents, along with 9 administrative licenses [2]

Core Viewpoint - Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. is holding its first extraordinary general meeting of shareholders in 2025 to discuss key proposals including the completion of fundraising projects and the election of independent directors [1][2]. Group 1: Meeting Agenda - The meeting is scheduled for July 14, 2025, at 14:30, lasting half a day, at the company's conference room in Suzhou, Jiangsu Province [1]. - The agenda includes the announcement of the meeting's start, attendance verification, discussion of various proposals, shareholder speeches, voting, announcement of results, legal opinions, and conclusion of the meeting [3]. Group 2: Proposals - Proposal One: The company plans to conclude the fundraising project for the generic drugs Linezolid and Voriconazole, reallocating the remaining funds to permanently supplement working capital for daily operations and business development, enhancing the efficiency of fund usage and benefiting all shareholders [2]. - Proposal Two: The company proposes to elect new independent directors to replace resigning members, with candidates including Sheng Hui and Pan Xiaolin, who will also take on roles in the audit and nomination committees [2][4].

Group 1 - The company Jiangsu Wuzhong Pharmaceutical Development Co., Ltd. (*ST Suwu, stock code: 600200) has been investigated by the China Securities Regulatory Commission (CSRC), which may lead to a forced delisting if major violations are confirmed [1] - The company faces financial delisting risks due to its 2024 financial report receiving a disclaimer of opinion from the auditing firm, triggering delisting risk warnings from the Shanghai Stock Exchange [2] - The company's financial situation is deteriorating, with declining revenue and profits, and increasing debt pressure, indicating serious financial distress [2] Group 2 - A significant issue arose when the chairman of the company's wholly-owned subsidiary was criminally charged for fraudulently obtaining export tax rebates, highlighting internal management and compliance failures [2] - This criminal case could severely damage the company's reputation and creditworthiness, impacting its business expansion and financing capabilities [2] - Investors who purchased shares before February 26, 2025, and sold or still hold them as of February 27, 2025, may be eligible for compensation, pending court validation [3]